TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal

TransCode Therapeutics ( (RNAZ) ) just unveiled an update.

TransCode Therapeutics, Inc. is a Boston-based clinical-stage biotechnology company pioneering immuno-oncology and RNA therapies for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, and the company is building a portfolio of first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells.

The company focuses on novel modalities such as RNA-targeted agents and oncolytic platforms to address solid tumors with significant unmet medical need. TransCode is listed on Nasdaq under the ticker RNAZ and is advancing its pipeline through early-stage clinical development and strategic licensing transactions in oncology.

On March 2, 2026, TransCode filed a Certificate of Designation in Delaware creating a new Series C Non-Voting Convertible Preferred Stock, which carries no dividends or general voting rights but ranks pari passu with common stock and existing preferred series in liquidation and includes protective provisions limiting adverse changes and further issuances. Conversion into common stock will only occur after specific stockholder approval and is subject to a beneficial ownership cap initially set at 4.99% per holder, with limited flexibility to adjust that cap.

On March 2, 2026, the company also entered into an exclusive licensing agreement with Unleash Immuno Oncolytics, Inc., acquiring a preclinical program of genetically engineered oncolytic adenoviruses and a perpetual, worldwide, fully paid-up, royalty-free license to related technology, in exchange for 1,136,364 shares of the new Series C Preferred Stock. TransCode additionally issued 77,841 Series C Preferred shares to Tungsten Advisors as financial advisory compensation, and plans to register the underlying shares via a Form S-3 and seek shareholder approval for conversion under Nasdaq rules.

In a March 3, 2026 announcement, TransCode detailed that the deal brings in three Unleash candidates—UIO-524, UIO-525 and UIO-526—anchored by UIO-524, a next-generation, biology-driven oncolytic adenovirus immunotherapy aimed initially at muscle-invasive bladder cancer, a high-cost, multi-billion-dollar global indication with poor outcomes and limited durable options. Management framed UIO-524 as complementary to Phase 2a-bound TTX-MC138, giving the company another high-upside shot on goal in aggressive solid tumors while broadening its early-stage pipeline and potentially strengthening its positioning in the competitive immuno-oncology market.

The licensing transaction adds a differentiated adenovirus platform that selectively replicates in malignant and stromal cells and delivers a multi-cytokine immune payload, positioning TransCode to compete in next-generation oncolytic therapies beyond earlier agents such as CG0070. For stakeholders, the all-stock structure avoids near-term cash outlays while diluting existing holders, with future impact hinging on successful clinical development, shareholder approval to convert the preferred stock, and regulatory clearance of the planned registration statement.

The most recent analyst rating on (RNAZ) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.

Spark’s Take on RNAZ Stock

According to Spark, TipRanks’ AI Analyst, RNAZ is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, widening losses, and ongoing cash burn), with limited valuation support due to continued losses. Offsetting factors include constructive near-term technical momentum and positive corporate developments around the pipeline and planned Phase 2a work, though high volatility and stretched oscillators temper the technical contribution.

To see Spark’s full report on RNAZ stock, click here.

More about TransCode Therapeutics

TransCode Therapeutics, Inc. is a Boston-based clinical-stage biotechnology company pioneering immuno-oncology and RNA therapies for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, and the company is building a portfolio of first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells.

The company focuses on novel modalities such as RNA-targeted agents and oncolytic platforms to address solid tumors with significant unmet medical need. TransCode is listed on Nasdaq under the ticker RNAZ and is advancing its pipeline through early-stage clinical development and strategic licensing transactions in oncology.

On March 2, 2026, TransCode filed a Certificate of Designation in Delaware creating a new Series C Non-Voting Convertible Preferred Stock, which carries no dividends or general voting rights but ranks pari passu with common stock and existing preferred series in liquidation and includes protective provisions limiting adverse changes and further issuances. Conversion into common stock will only occur after specific stockholder approval and is subject to a beneficial ownership cap initially set at 4.99% per holder, with limited flexibility to adjust that cap.

On March 2, 2026, the company also entered into an exclusive licensing agreement with Unleash Immuno Oncolytics, Inc., acquiring a preclinical program of genetically engineered oncolytic adenoviruses and a perpetual, worldwide, fully paid-up, royalty-free license to related technology, in exchange for 1,136,364 shares of the new Series C Preferred Stock. TransCode additionally issued 77,841 Series C Preferred shares to Tungsten Advisors as financial advisory compensation, and plans to register the underlying shares via a Form S-3 and seek shareholder approval for conversion under Nasdaq rules.

In a March 3, 2026 announcement, TransCode detailed that the deal brings in three Unleash candidates—UIO-524, UIO-525 and UIO-526—anchored by UIO-524, a next-generation, biology-driven oncolytic adenovirus immunotherapy aimed initially at muscle-invasive bladder cancer, a high-cost, multi-billion-dollar global indication with poor outcomes and limited durable options. Management framed UIO-524 as complementary to Phase 2a-bound TTX-MC138, giving the company another high-upside shot on goal in aggressive solid tumors while broadening its early-stage pipeline and potentially strengthening its positioning in the competitive immuno-oncology market.

The licensing transaction adds a differentiated adenovirus platform that selectively replicates in malignant and stromal cells and delivers a multi-cytokine immune payload, positioning TransCode to compete in next-generation oncolytic therapies beyond earlier agents such as CG0070. For stakeholders, the all-stock structure avoids near-term cash outlays while diluting existing holders, with future impact hinging on successful clinical development, shareholder approval to convert the preferred stock, and regulatory clearance of the planned registration statement.

Average Trading Volume: 265,227

Technical Sentiment Signal: Sell

Current Market Cap: $9.05M

For a thorough assessment of RNAZ stock, go to TipRanks’ Stock Analysis page.